PMID- 29954090
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 6
IP  - 3
DP  - 2018 Jun 27
TI  - Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved 
      from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.
LID - 10.3390/pharmacy6030057 [doi]
LID - 57
AB  - Type 2 Diabetes Mellitus (T2DM) is the most common form of diabetes mellitus and 
      accounts for about 95% of all diabetes cases. Many newer oral as well as 
      parenteral antidiabetic drugs have been introduced in to the market in recent 
      years to control hyperglycemic conditions in diabetes patients and many of these 
      drugs produce potential side effects in diabetes patients. Hence, this systematic 
      review was aimed to analyze and compare the efficacy and safety of oral 
      antidiabetic agents in controlling HbA1c in T2DM patients, that were approved by 
      the United States-Food and Drug Administration (US-FDA) from 2013 to 2017. All 
      randomized controlled, double-blind trials published in English during the search 
      period involving the newer antidiabetic agents were selected. In the outcome 
      assessment comparison, semaglutide demonstrated the highest efficacy in lowering 
      HbA1c, with a 1.6% reduction (p < 0.0001) when given at a dose of 1.0 mg. The 
      safety profile of all the agents as compared to placebo or control were similar, 
      with no or slight increase in the occurrence of adverse events (AEs) but no fatal 
      reaction was reported. The most common AEs of all the antidiabetic agents were 
      gastrointestinal in nature, with several cases of hypoglycemic events. However, 
      among all these agents, semaglutide seems to be the most efficacious drug to 
      improve glycemic control in terms of HbA1c. Alogliptin has the least overall 
      frequency of AEs compared to other treatment groups.
FAU - Palanisamy, Sivanandy
AU  - Palanisamy S
AUID- ORCID: 0000-0002-1844-8108
AD  - Department of Pharmacy Practice, International Medical University, Kuala Lumpur 
      57000, Malaysia. PalanisamySivanandy@imu.edu.my.
FAU - Yien, Emily Lau Hie
AU  - Yien ELH
AD  - School of Pharmacy, International Medical University, Kuala Lumpur 57000, 
      Malaysia. emilie_0705@hotmail.com.
FAU - Shi, Ling Wen
AU  - Shi LW
AD  - School of Pharmacy, International Medical University, Kuala Lumpur 57000, 
      Malaysia. lingwenshi@hotmail.com.
FAU - Si, Low Yi
AU  - Si LY
AD  - School of Pharmacy, International Medical University, Kuala Lumpur 57000, 
      Malaysia. yisilow95@gmail.com.
FAU - Qi, See Hui
AU  - Qi SH
AD  - School of Pharmacy, International Medical University, Kuala Lumpur 57000, 
      Malaysia. huiqi0325@gmail.com.
FAU - Ling, Laura Soon Cheau
AU  - Ling LSC
AD  - School of Pharmacy, International Medical University, Kuala Lumpur 57000, 
      Malaysia. laura_son@hotmail.com.
FAU - Lun, Teng Wai
AU  - Lun TW
AD  - School of Pharmacy, International Medical University, Kuala Lumpur 57000, 
      Malaysia. ashteng.96@gmail.com.
FAU - Chen, Yap Nee
AU  - Chen YN
AD  - School of Pharmacy, International Medical University, Kuala Lumpur 57000, 
      Malaysia. alicemuimail@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180627
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC6164486
OTO - NOTNLM
OT  - antidiabetic agent
OT  - diabetes mellitus
OT  - efficacy
OT  - glycosylated hemoglobin
OT  - safety
COIS- The authors declare no conflict of interest.
EDAT- 2018/06/30 06:00
MHDA- 2018/06/30 06:01
PMCR- 2018/06/27
CRDT- 2018/06/30 06:00
PHST- 2018/04/25 00:00 [received]
PHST- 2018/06/01 00:00 [revised]
PHST- 2018/06/21 00:00 [accepted]
PHST- 2018/06/30 06:00 [entrez]
PHST- 2018/06/30 06:00 [pubmed]
PHST- 2018/06/30 06:01 [medline]
PHST- 2018/06/27 00:00 [pmc-release]
AID - pharmacy6030057 [pii]
AID - pharmacy-06-00057 [pii]
AID - 10.3390/pharmacy6030057 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2018 Jun 27;6(3):57. doi: 10.3390/pharmacy6030057.